Table 1.
Patient characteristics and the proportion of receiving Oncotype DX test by patient characteristics, hormone receptor-positive breast cancer patients from 17 SEER registries, 2004–2015 (N = 390,396)
| N0 (N = 288,684) |
N1 (N = 101,712) |
|||
|---|---|---|---|---|
| % | % of patients with ODX | % | % of patients with ODX | |
|
| ||||
| All | 31.47 | 14.76 | ||
| Age | P < 0.0001 | P < 0.0001 | ||
| < 50 | 17.41 | 41.16 | 27.77 | 10.92 |
| 50–59 | 22.64 | 42.10 | 26.24 | 15.75 |
| 60–69 | 27.48 | 37.03 | 24.02 | 19.50 |
| 70–79 | 20.64 | 20.05 | 14.63 | 17.52 |
| ≥ 80 | 11.83 | 3.86 | 7.34 | 4.75 |
| Race/ethnicity | P < 0.0001 | P < 0.0001 | ||
| NH white | 75.11 | 31.32 | 70.03 | 15.63 |
| NH black | 7.69 | 32.05 | 10.03 | 12.28 |
| NH American Indian/Alaska Native | 0.39 | 31.66 | 0.44 | 14.77 |
| NH Asian or Pacific Islander | 7.73 | 32.55 | 7.89 | 13.69 |
| Hispanic (all races) | 8.69 | 31.08 | 11.23 | 12.31 |
| NH unknown race | 0.38 | 35.50 | 0.38 | 16.15 |
| Marital status | P < 0.0001 | P < 0.0001 | ||
| Married | 55.64 | 35.40 | 57.25 | 15.74 |
| Single | 12.48 | 33.43 | 14.25 | 14.03 |
| Other | 27.52 | 22.64 | 24.47 | 12.91 |
| Unknown | 4.36 | 31.44 | 4.03 | 14.80 |
| Insurance type (2007–2015) | P < 0.0001 | P < 0.0001 | ||
| Insured | 75.01 | 38.17 | 71.99 | 19.42 |
| Medicaid | 8.48 | 33.34 | 11.63 | 13.49 |
| Insured but insurance type not specified | 13.74 | 34.76 | 13.14 | 18.76 |
| Uninsured | 1.08 | 39.48 | 1.67 | 15.27 |
| Unknown | 1.69 | 38.25 | 1.57 | 19.12 |
| Tumor grade | P < 0.0001 | P < 0.0001 | ||
| Well differentiated | 28.14 | 29.43 | 16.85 | 22.50 |
| Moderately differentiated | 48.53 | 34.48 | 49.37 | 16.53 |
| Poorly differentiated/undifferentiated | 20.46 | 28.15 | 30.48 | 8.26 |
| Unknown | 2.86 | 24.14 | 3.30 | 8.91 |
| Tumor size, cm | P < 0.0001 | P < 0.0001 | ||
| 0.6–2.0 for N0 or ≤ 2.0 for N1 | 74.33 | 32.21 | 47.29 | 19.45 |
| 2.1–5.0 | 23.29 | 30.59 | 44.00 | 11.54 |
| > 5.0 | 2.38 | 16.84 | 8.71 | 5.60 |
| Surgery & reported radiation | P < 0.0001 | P < 0.0001 | ||
| Mastectomy, no/unknown radiation | 32.28 | 30.39 | 36.43 | 13.16 |
| Mastectomy, radiation | 2.76 | 24.94 | 18.47 | 8.63 |
| Lumpectomy, no/unknown radiation | 16.79 | 20.86 | 12.65 | 13.03 |
| Lumpectomy, radiation | 48.17 | 36.27 | 32.44 | 20.73 |
| Reported chemotherapy | P < 0.0001 | P < 0.0001 | ||
| Yes | 23.73 | 28.89 | 63.20 | 8.12 |
| No/unknown | 76.27 | 32.27 | 36.80 | 26.17 |
| State/area | P < 0.0001 | P < 0.0001 | ||
| California | 41.17 | 26.00 | 40.97 | 13.23 |
| Connecticut | 5.59 | 34.85 | 4.81 | 16.18 |
| Georgia | 10.18 | 38.38 | 10.84 | 15.98 |
| Hawaii | 1.92 | 38.04 | 1.71 | 18.34 |
| Iowa | 4.02 | 27.20 | 3.80 | 13.43 |
| Kentucky | 5.37 | 30.29 | 4.96 | 13.21 |
| Louisiana | 4.46 | 34.31 | 4.84 | 15.36 |
| Detroit | 5.02 | 39.25 | 5.24 | 17.10 |
| New Jersey | 11.26 | 41.52 | 11.41 | 17.98 |
| New Mexico | 2.00 | 41.27 | 2.09 | 21.05 |
| Utah | 2.20 | 27.31 | 2.66 | 9.33 |
| Seattle | 6.81 | 27.24 | 6.68 | 14.59 |
| Recurrence score (original cutoff points)a | – | – | ||
| Low (< 18) | 56.52 | – | 59.36 | – |
| Intermediate (18–30) | 35.74 | – | 34.08 | – |
| High (≥ 31) | 7.74 | – | 6.56 | – |
| Recurrence score (TAILOXr cutoff points)a | – | – | ||
| Low (< 11) | 20.52 | – | 21.72 | – |
| Intermediate (11–25) | 64.29 | – | 64.98 | – |
| High (≥ 26) | 15.19 | – | 13.30 | – |
N0 with negative axillary lymph node, N1 with 1–3 positive ipsilateral axillary lymph nodes, ODX Oncotype DX, NH non-Hispanic
a
Among patients who had Recurrence Score